Leerink Partners Starts Protagonist Therapeutics (PTGX) at Outperform

September 6, 2016 6:24 AM EDT
Get Alerts PTGX Hot Sheet
Price: $17.63 -0.79%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 18 | Down: 18 | New: 11
Trade PTGX Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Leerink Partners initiates coverage on Protagonist Therapeutics (NASDAQ: PTGX) with a Outperform rating and a price target of $17.00.

Analyst Joseph Schwartz commented, "Protagonist is aiming to become the standard of care therapy for moderate to severe Irritable Bowel Disease (IBD) patients, a large and growing market opportunity. Currently approved therapies are insufficient, with upwards of 50% of moderate and severe IBD patients failing to achieve a sustained response to currently available treatments. Herein we discuss PTGX's currently planned clinical programs along with our perceived strengths and outstanding questions."

For an analyst ratings summary and ratings history on Protagonist Therapeutics click here. For more ratings news on Protagonist Therapeutics click here.

Shares of Protagonist Therapeutics closed at $12.08 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Add Your Comment